Catalysts for Eisai Co Ltd

Eisai Co Ltd — lenvatinib mesylate (Drug Expiry (US))

Eisai Co Ltd — lenvatinib mesylate (Constraining Patent Expiry (US))

ERIBULIN MESYLATE — FDA approval

LEQEMBI (LECANEMAB-IRMB) — FDA approval

LEQEMBI (LECANEMAB-IRMB) — FDA approval

LEQEMBI (LECANEMAB-IRMB) — FDA approval

LEQEMBI (LECANEMAB-IRMB) — FDA approval

LEQEMBI (LECANEMAB-IRMB) — FDA approval

LEQEMBI (LECANEMAB-IRMB) — FDA approval

LEQEMBI (LECANEMAB-IRMB) — FDA approval

LEQEMBI (LECANEMAB-IRMB) — FDA approval

NCT04238715: A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion